Safety committee recommends starting top-dose cohort in Entrada study
The independent safety data monitoring committee recommended initiating Cohort 3 at the top dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 study.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.